陌brahim Bilen路 @drbilennn 路 X路路 11 hours agoScore70
Body 路 original
Breaking from the #ESMO26 Presidential Symposium! 馃毃
The Phase 3 DeLLphi-305 trial results mark a historic shift in first-line maintenance therapy for extensive-stage small cell lung cancer.
22 views 路 0 likes 路 0 reposts 路 0 replies
Conference abstracts
LBA3matched by Presidential Symposium I
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgSource: 陌brahim Bilen 路 x.com